HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Twinlab Finds Potential Buyer In IdeaSphere: End Of Blechman Era?

This article was originally published in The Tan Sheet

Executive Summary

The proposed acquisition of Twinlab by nutritional products seller IdeaSphere would mark the end of the Blechman family ownership of the company, in place since the company's founding 35 years ago

You may also be interested in...



IdeaSphere markets Weil

IdeaSphere will "assume exclusive, worldwide licensing rights" to Weil Nutritional Supplements, the New York-based firm announced Jan. 17. The product line, which was launched in March by author Andrew Weil, MD, currently is sold through Weil's website and in specialty health stores such as Whole Foods, GNC and Vitamin Shoppe. IdeaSphere will take over retail and direct marketing of the supplement line including online sales, the company states. IdeaSphere purchased Twinlab in 2003 and most recently completed the acquisition of Metabolife's non-ephedra brands including Metabolife Ultra in November (1"The Tan Sheet" Sept. 1, 2003, p. 3 and 2"The Tan Sheet" Nov. 14, 2005, In Brief)...

Twinlab Goes In For The Krill With Product Launches, Promotional Deals

IdeaSphere used the Natural Products Expo West trade show as a platform to introduce a host of Twinlab vitamins and supplements to the market

Twinlab Sells Assets To IdeaSphere, Files For Protection From Creditors

IdeaSphere will acquire all assets of dietary supplement manufacturer Twinlab for $65 mil. following the company's filing for Chapter 11 bankruptcy

Related Content

Topics

UsernamePublicRestriction

Register

LL1135490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel